LivaNova (NASDAQ:LIVN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, November 9th. The brokerage presently has a $89.00 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 0.90% from the company’s previous close.
According to Zacks, “LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company’s operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. “
Several other equities analysts have also weighed in on LIVN. Berenberg Bank reissued a “buy” rating and issued a $70.00 price objective on shares of LivaNova in a research report on Friday, August 11th. Needham & Company LLC started coverage on shares of LivaNova in a research report on Wednesday, August 23rd. They set a “hold” rating on the stock. Canaccord Genuity restated a “hold” rating and set a $71.00 price target on shares of LivaNova in a report on Wednesday, September 20th. WBB Securities downgraded shares of LivaNova from a “hold” rating to a “sell” rating and set a $50.00 price target on the stock. in a report on Tuesday, August 15th. Finally, BidaskClub cut LivaNova from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. LivaNova currently has a consensus rating of “Buy” and a consensus price target of $79.14.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Thursday, November 2nd. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.17. The business had revenue of $309.70 million for the quarter, compared to analyst estimates of $301.22 million. LivaNova had a net margin of 4.63% and a return on equity of 9.33%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.78 EPS. sell-side analysts expect that LivaNova will post 3.33 earnings per share for the current year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $68.55, for a total value of $68,550.00. Following the transaction, the director now directly owns 57,296 shares of the company’s stock, valued at $3,927,640.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Alfred J. Novak sold 2,000 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $85.77, for a total value of $171,540.00. The disclosure for this sale can be found here. Insiders sold a total of 5,000 shares of company stock valued at $396,060 over the last quarter. Company insiders own 0.28% of the company’s stock.
A number of hedge funds have recently bought and sold shares of LIVN. PNC Financial Services Group Inc. boosted its position in shares of LivaNova by 9.8% during the second quarter. PNC Financial Services Group Inc. now owns 1,707 shares of the company’s stock worth $105,000 after buying an additional 153 shares during the period. Riverhead Capital Management LLC boosted its holdings in LivaNova by 76.3% in the second quarter. Riverhead Capital Management LLC now owns 1,763 shares of the company’s stock valued at $108,000 after purchasing an additional 763 shares during the period. Shelton Capital Management purchased a new stake in LivaNova during the 3rd quarter worth about $209,000. Exane Derivatives lifted its holdings in LivaNova by 814.8% during the 2nd quarter. Exane Derivatives now owns 3,156 shares of the company’s stock worth $158,000 after buying an additional 2,811 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in LivaNova during the 2nd quarter worth about $204,000. 86.07% of the stock is owned by institutional investors.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with our FREE daily email newsletter.